

NOVADEL PHARMA INC

Form 8-K

November 14, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 2, 2011

NOVADEL PHARMA INC.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or other jurisdiction  
of incorporation or  
organization)

001-32177  
(Commission File No.)

22-2407152  
(I.R.S. Employer  
Identification No.)

1200 Route 22 East, Suite 2000  
Bridgewater, NJ 08807  
(Address of principal executive offices) (Zip Code)

(908) 203-4640  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
-

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement.

On November 2, 2011, NovaDel Pharma Inc., a Delaware corporation, (the "Company") entered into a settlement of claims (the "Settlement Agreement") arising under the June 22, 2004 Second Amendment to the License and Development Agreement by and between the Company and The Veterinary Company, Inc. n/k/a Velcera, Inc. ("Velcera") (the "License Agreement") whereby Velcera agreed to pay \$250,000 in full and final satisfaction of any amounts owed under the License Agreement including any future milestone or royalty obligations. The parties agreed that the License Agreement shall otherwise remain in full force and effect. The Company received the \$250,000 on November 8, 2011.

A complete copy of the Settlement Agreement is attached to this Form 8-K. The foregoing description of the Settlement Agreement is qualified in its entirety by reference to such document.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
Exhibit No.	Description
10.1	Settlement of Claims Arising Under June 22, 2004 Second Amendment to License and Development Agreement by and between NovaDel Pharma Inc. and The Veterinary Company, Inc. (n/k/a Velcera, Inc.)

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma Inc.

By: /s/ STEVEN B.  
RATOFF  
Name: Steven B. Ratoff  
Title: President, Chief  
Executive Officer  
and Interim Chief  
Financial Officer

Date: November 14, 2011